Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Precision Biosciences Inc.
Headquarters: Durham, NC, United States of America
Website: http://www.precisionbioscie...
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Michael Amoroso, EMBA
Number Of Employees: 108
Enterprise Value: $-30,039,299
PE Ratio: 2.49
Exchange/Ticker 1: NASDAQ:DTIL
Exchange/Ticker 2: N/A
Latest Market Cap: $19,141,300
BioCentury | Jan 30, 2025
Management Tracks
Wyman joins Scholar Rock
Plus: Danilkowicz to lead commercial at Alumis and an update from Precision
BioCentury | Apr 23, 2024
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
BioCentury | Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
BioCentury | Jan 9, 2024
Deals
Jan. 9 Quick Takes: Precision deal gets TG entry into autoimmune CAR T race
Plus: Pfizer’s, Genmab’s Tivdak gets priority review for full approval and more from Astellas, Cumulus, Pfizer and Innovent
BioCentury | Dec 9, 2023
Regulation
Two sickle cell gene therapies enter U.S. market, but can both succeed?
FDA approves pair of sickle cell therapies with curative potential, but safety and pricing concerns cloud bluebird’s commercial path
BioCentury | Sep 28, 2023
Management Tracks
Expanded role for Gaito at J.P. Morgan
Plus: Peptone hires a new CSO, names Gritstone’s Allen chair, and updates from Foresite, OncoC4, Sibylla, Cell-Easy and Photocure
BioCentury | Aug 17, 2023
Finance
Aug. 16 Quick Takes: CirCode follows Pfizer deal with JJDC-led series A
Plus: At last, approval Ipsen FOP therapy Sohono and updates from Compass Pathways, Day One-Sprint, Seagen, Artiva, Precision-Imugene, Impel
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Feb 25, 2023
Management Tracks
Delfi promotes Buechel to president and COO
Plus: changes at Precision and updates for the TB Alliance and FDA
BioCentury | Oct 8, 2022
Deals
Oct. 7 Quick Takes: label expansion for Alnylam’s Oxlumo
Plus Allogeneic CAR T advances to potentially pivotal trial and Makena update
Items per page:
1 - 10 of 76